SAN DIEGO, May 2, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with a commercial liquid biopsy technology focused on cancer treatment and monitoring, announces that management will make a corporate presentation at Joseph Gunnar & Co.'s inaugural PIONEERS 2016 Conference on Thursday, May 5, 2016, at 9:00 a.m. Eastern time. The conference is being held at The New York Palace Hotel in New York City.
Mr. Nall will be available for one-on-one meetings with the investment community on Thursday, May 5. Please contact LHA at 310-691-7100 if you would like to arrange a meeting. The corporate presentation from the event will be available on the Company's website at ir.biocept.com.
Biocept, Inc. is a molecular diagnostics company with commercial tests targeting lung, breast, gastric, colorectal and prostate cancers and melanoma. The company uses its proprietary liquid biopsy technology to provide physicians with more precise information for treating and monitoring patients with cancer. The company's patented Target Selector™ liquid biopsy technology platform captures and analyzes circulating tumor DNA in both circulating tumor cells (CTCs) and in plasma (ctDNA). After thousands of tests, the platform has proven to be effective in identifying cancer mutations. Biocept plans to introduce additional CLIA-validated tests in the near term. For additional information, please visit www.biocept.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-inaugural-joseph-gunnar-pioneers-2016-conference-300260446.html
SOURCE Biocept, Inc.